OncLive TV

Sara Nunnery, MD, MSCI, discusses genomic testing, ovarian function suppression, and toxicity management in hormone receptor–positive breast cancer.

Kelsey H. Natsuhara, MD, discusses emerging ADCs and the importance of clinical trial enrollment in triple-negative breast cancer.

Floor Backes, MD, discusses BEHOLD-1 data for the B7-H4–directed ADC mocertatug rezetecan in platinum-resistant ovarian cancer.

Shiven B. Patel, MD, MBA, FACP, discusses how zidesamtinib compares with taletrectinib in ROS1-positive non–small cell lung cancer.

Marcelo V. Negrao, MD, discusses updated efficacy and safety data for first-line olomorasib plus chemoimmunotherapy in KRAS G12C–mutant NSCLC.

Lauren Banks, MD, PhD, discusses feasibility findings for lifileucel in select metastatic sarcomas and next steps with the phase 2 SARATOGA trial.

Justin Moser, MD, discusses safety and activity of the IL-2 prodrug WTX-124 alone or with pembrolizumab in immune-sensitive solid tumors.

Steven Isakoff, MD, PhD, MMSc, discusses data for invikafusp alfa plus sacituzumab govitecan in advanced HR-positive or triple-negative breast cancer.

Laura Graham, MD, discusses phase 1 safety and PSA response data for JNJ-87189401 plus pasritamig in metastatic castration-resistant prostate cancer.

Yana Najjar, MD, discusses phase 1/1b STEALTH-001 data for the oncolytic virus VET3-TGI in advanced solid tumors, including cutaneous cancers.

Daniel W. Lee, III, MD, discusses a case study of polatuzumab vedotin/glofitamab and CD19 CAR T-cell therapy in a child with refractory Burkitt lymphoma.

Suzanne B. Merrill, MD, discusses patient selection and toxicity considerations for BCG plus durvalumab in BCG-naive, high-risk NMIBC.

Benjamin Garmezy, MD, discusses how biomarkers, toxicity, and patient preferences guide treatment intensification in advanced prostate cancer.

Ferdinandos Skoulidis, MD, PhD, MRCP, discusses survival and safety data for divarasib vs sotorasib or adagrasib in KRAS G12C–mutated NSCLC.

Qingqing Cai, MD, PhD, explains why the dual-binding profile of rocbrutinib supports pairing it with R-CHOP for newly diagnosed B-cell lymphoma.

Shannon N. Westin, MD, MPH, FACOG, discusses development strategies and combination potential for B7-H4–directed ADCs in gynecologic cancers.

Ignacio Garrido-Laguna, MD, PhD, MBA, discusses early efficacy and safety of QTX3034 plus cetuximab with or without mFOLFOX6 in KRAS G12D–mutant CRC.

James J. Harding, MD, and Jian Zhou, MD, PhD, compare first-line biliary tract cancer care in the US and China and discuss HARMONi-GI1.

Pasi A. Jänne, MD, PhD, and Yi-Long Wu, MD, FACS, compare first-line EGFR-mutated NSCLC care in the US and China and discuss SAFFRON and SANOVO.

Doris Hansen, MD, discusses the potential role of GPRC5D-directed CAR T-cell therapy with arlo-cel in patients with multiple myeloma.

Federica Gatti, MD, discusses the prognostic impact of ESR1 mutations and genomic co-alterations in HR+/HER2– metastatic breast cancer.

Daniel Heng, MD, MPH, FRCPC, discusses first-line treatment selection and the role of second-line belzutifan plus lenvatinib in advanced RCC.

Meredith McKean, MD, MPH, discusses uveal melanoma biology, prognostic testing, surveillance, and next steps for tebentafusp.

Paul L. Swiecicki, MD, discusses first-line amivantamab plus pembrolizumab and carboplatin in recurrent/metastatic head and neck cancer.

Georgina V. Long, AO, BSc, PhD, MBBS, discusses phase 3 INTerpath-001 data for adjuvant intismeran autogene plus pembrolizumab in melanoma.

Dana M. Chase, MD, discusses updated BEHOLD-1 data for mocertatug rezetecan and where B7-H4–targeted ADCs may fit in platinum-resistant ovarian cancer.

Darren R. Feldman, MD, details early response and disease control findings with a claudin 6–directed antibody-drug conjugate in relapsed germ cell tumors.

Johanna Enke, MD, discusses safety findings from a phase 2 study of lutetium Lu 177 vipivotide tetraxetan rechallenge in mCRPC.

Shannon N. Westin, MD, MPH, FACOG, discusses interim overall survival data from the phase 3 DUO-E trial in advanced or recurrent endometrial cancer.

P. Leia Nghiemphu, MD, discusses how the NCCN guideline inclusion of brigatinib expands treatment access for patients with NF2-related schwannomatosis.